Related Experiment Video

Updated: Mar 20, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

[Melanoma]

Hisashi Uhara1

  • 1Dept. of Dermatology, Shinshu University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 26, 2016
PubMed

Insights

Effective treatments for metastatic melanoma, including BRAF/MEK inhibitors and immune checkpoint inhibitors, offer significant survival benefits. Ongoing research explores new combination therapies to further improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Context:

  • Metastatic melanoma treatment has advanced significantly since 2011.
  • Several targeted therapies and immunotherapies are now available.

Purpose:

  • To review the efficacy of current and emerging treatments for metastatic melanoma.
  • To highlight the impact of combination therapies on patient survival and response rates.

Summary:

  • BRAF and MEK inhibitor combinations yield ~70% response rates and >11 months progression-free survival.
  • Ipilimumab and nivolumab combination shows 60-70% response rates and 11-14 months progression-free survival, with noted toxicities.
  • Numerous clinical trials are investigating novel combination strategies.

Impact:

  • These advancements offer improved therapeutic options for patients with metastatic melanoma.
  • Combination therapies represent a key strategy in enhancing treatment efficacy.
  • Further research in combination therapies promises continued progress in melanoma management.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
Pigmentation01:19

Pigmentation

The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.4K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.2K